Cargando…

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine

Pegaspargase combined with gemcitabine have greatly improved the outcomes of advanced extranodal NK/T cell lymphoma (ENKL). However, patients frequently undergo recurrent disease due to chemoresistance, and few predictive parameters are available. The present study explored potential biomarkers to p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhiyuan, Li, Zhaoming, Sun, Zhenchang, Zhang, Xudong, Lu, Lisha, Wang, Yingjun, Zhang, Mingzhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810364/ https://www.ncbi.nlm.nih.gov/pubmed/27021626 http://dx.doi.org/10.1038/srep23695

Ejemplares similares

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma
por: Fu, Ruiying, et al.
Publicado: (2023)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus
por: Zhao, Qian, et al.
Publicado: (2019)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

P1238: EFFICACY ANALYSIS OF PEGASPARGASE, GEMCITABINE, OXALIPLATIN, DEXAMETHASONE COMBINED WITH TISLELIZUMAB IN FIRST-LINE TREATMENT OF PLASMA EBV-DNA POSITIVE EXTRANODAL NK/T CELL LYMPHOMA
por: Yuan, X., et al.
Publicado: (2022)

Circulating Low Absolute CD4(+) T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy
por: Zhang, Ya-Ping, et al.
Publicado: (2019)

Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate
por: Zhou, Zhiyuan, et al.
Publicado: (2021)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Extranodal T- and NK-cell lymphomas
por: de Leval, Laurence, et al.
Publicado: (2022)

An autopsy case of primary extranodal NK/T cell lymphoma (extranodal NK/T-cell lymphoma) of the bile duct
por: Ito, Hiroyuki, et al.
Publicado: (2019)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes
por: Fu, Xiaorui, et al.
Publicado: (2017)

Laryngeal recurrence of extranodal NK/T cell lymphoma
por: Kumai, Takumi, et al.
Publicado: (2021)

Leukemic presentation of extranodal NK/T‐cell lymphoma
por: Hafeez, Safina, et al.
Publicado: (2021)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019)

Extranodal NK/T-cell Lymphoma Mimicking Erythema Multiforme
por: Xia, Ying, et al.
Publicado: (2015)

Extranodal NK/T Cell Lymphoma Causing Cardiorespiratory Failure
por: Li, Yiting, et al.
Publicado: (2016)

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
por: Hu, Boyu, et al.
Publicado: (2018)

Extranodal NK/T-cell Lymphoma Mimicking Granulomatous Myositis
por: Kawaguchi, Norihiko, et al.
Publicado: (2018)

Molecular pathogenic pathways in extranodal NK/T cell lymphoma
por: de Mel, Sanjay, et al.
Publicado: (2019)

Extranodal NK/T-Cell Lymphoma Mimicking an Infectious Granuloma
por: Suh, Min Song, et al.
Publicado: (2019)

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma
por: Kim, Hyunsung, et al.
Publicado: (2022)

Extranodal NK/T Cell Lymphoma Mimicking Behçet's Syndrome
por: Wang, Youyang, et al.
Publicado: (2021)

Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
por: Major, Ajay, et al.
Publicado: (2023)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3
por: Mei, Mei, et al.
Publicado: (2021)

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review
por: Lin, Li, et al.
Publicado: (2017)

Extranodal NK/T-cell lymphoma presenting with primary cardiac involvement
por: Lepeak, Lisa M., et al.
Publicado: (2011)

Icaritin induces lytic cytotoxicity in extranodal NK/T-cell lymphoma
por: Wu, Ting, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lrc488lkoaoefg2sj846ng13um